Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

2.

Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?

Verguet S, Stalcup M, Walsh JA.

Sex Transm Infect. 2013 Dec;89(8):628-34. doi: 10.1136/sextrans-2012-050891. Epub 2013 Aug 2. Review.

PMID:
23912819
3.

The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.

Mdege ND, Chindove S, Ali S.

Health Policy Plan. 2013 May;28(3):223-36. doi: 10.1093/heapol/czs058. Epub 2012 Jun 26. Review.

4.

Cost-effectiveness of antiretroviral therapy for prevention.

Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R.

Curr HIV Res. 2011 Sep;9(6):405-15. Review.

5.

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.

Creese A, Floyd K, Alban A, Guinness L.

Lancet. 2002 May 11;359(9318):1635-43. Review. Erratum in: Lancet 2002 Sep 14;360(9336):880.

PMID:
12020523
6.

HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.

Delva W, Eaton JW, Meng F, Fraser C, White RG, Vickerman P, Boily MC, Hallett TB.

PLoS Med. 2012;9(7):e1001258. doi: 10.1371/journal.pmed.1001258. Epub 2012 Jul 10. Review.

7.

HIV treatment as prevention: issues in economic evaluation.

Bärnighausen T, Salomon JA, Sangrujee N.

PLoS Med. 2012;9(7):e1001263. doi: 10.1371/journal.pmed.1001263. Epub 2012 Jul 10. Review.

8.

The economics, financing and implementation of HIV treatment as prevention: what will it take to get there?

Wilson D, Taaffe J, Fraser-Hurt N, Gorgens M.

Afr J AIDS Res. 2014;13(2):109-19. doi: 10.2989/16085906.2014.943254. Review.

PMID:
25174628
9.

Antiretroviral therapy for prevention of HIV transmission: implications for Europe.

Cambiano V, O'Connor J, Phillips AN, Rodger A, Lodwick R, Pharris A, Lampe F, Nakagawa F, Smith C, van de Laar MJ.

Euro Surveill. 2013 Nov 28;18(48):20647. Review. Erratum in: Euro Surveill. 2014;19(11):pii/20739.

10.

Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis.

Granich R, Lo YR, Suthar AB, Vitoria M, Baggaley R, Obermeyer CM, McClure C, Souteyrand Y, Perriens J, Kahn JG, Bennett R, Smyth C, Williams B, Montaner J, Hirnschall G.

Curr HIV Res. 2011 Sep;9(6):355-66. Review.

11.

Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.

Kessler J, Braithwaite RS.

Curr Opin HIV AIDS. 2013 Nov;8(6):544-9. doi: 10.1097/COH.0000000000000005. Review.

12.

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.

Walensky RP, Ciaranello AL, Park JE, Freedberg KA.

Clin Infect Dis. 2010 Jul 1;51(1):85-92. doi: 10.1086/653119. Review.

13.

Antiretroviral adherence interventions in Southern Africa: implications for using HIV treatments for prevention.

Dewing S, Mathews C, Fatti G, Grimwood A, Boulle A.

Curr HIV/AIDS Rep. 2014 Mar;11(1):63-71. doi: 10.1007/s11904-013-0193-5. Review.

PMID:
24390683
14.

ART in South Africa: The price to pay.

Huyser C, Boyd L.

Facts Views Vis Obgyn. 2013;5(2):91-9. Review.

Items per page

Supplemental Content

Write to the Help Desk